Source link : https://yourblogdomain.com/2025/03/18/pembrolizumab-olaparib-boosts-pfs-in-non-brca-ovarian-cancer/
Source link : https://newshealth.biz/health-news/pembrolizumab-olaparib-boosts-pfs-in-non-brca-ovarian-cancer/ (MedPage Today) — A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a randomized trial showed. In… Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114711 Author : Publish date : 2025-03-18 16:19:00 Copyright for syndicated content belongs to the […]
—-
Author : yourblogdomain
Publish date : 2025-03-18 17:32:00
Copyright for syndicated content belongs to the linked Source.
Categories